The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.75
Bid: 18.50
Ask: 19.00
Change: -0.50 (-2.60%)
Spread: 0.50 (2.703%)
Open: 19.25
High: 19.25
Low: 18.75
Prev. Close: 19.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Interim Results and Webcast

19 Jan 2012 07:00

RNS Number : 8087V
Angle PLC
19 January 2012
 



For Immediate Release

 19 January 2012

 

 

ANGLE plc

("ANGLE" or the "Company")

 

 

Notice of Interim Results and Webcast - 26 January 2012

 

 

ANGLE plc (AIM: AGL) is pleased to announce that it will be releasing its interim results for the six months ended 31 October 2011 on Thursday 26 January 2012.

 

The interim results presentation will be given by Andrew Newland, Chief Executive Officer and Ian Griffiths, Finance Director.

 

Meetings

 

A meeting for analysts will be held at 10:00am on the morning of the results announcement at the offices of Buchanan Communications, 107 Cheapside, London EC2V 6DN.

 

A lunch meeting for Private Client Brokers will follow commencing at 12:30pm.

 

Webcast Details

 

Running in parallel with the analyst meeting will be a live webcast. Please log on 10 minutes before the start of the webcast at (09:50am GMT). The webcast log on address is:http://mediaserve.buchanan.uk.com/2012/angle260112/registration.asp.

 

A recording of the webcast will also be made available on ANGLE's website (www.ANGLEplc.com) following the results meeting.

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive Officer

Ian Griffiths, Finance Director

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts (Sales)

020 7397 8900

Buchanan

Lisa Baderoon

020 7466 5000 / 07721 413 496

Scott Harris

Stephen Scott, Harry Dee

020 7653 0030

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBCGDBUSBBGDI
Date   Source Headline
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer
7th Mar 20128:00 amRNSHolding(s) in the Company
28th Feb 201212:00 pmRNSDirector Share Transfer
28th Feb 20128:00 amRNSTotal Voting Rights
27th Feb 20127:00 amRNSParsortix Research Partnership
22nd Feb 20127:00 amRNSSecond Novocellus Patent

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.